Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.
Sauré D +10 more
europepmc +1 more source
Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration. [PDF]
Iglesias-Caballero M +22 more
europepmc +1 more source
iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering. [PDF]
Kunze R +7 more
europepmc +1 more source
Clesrovimab approval for RSV: a lifesaving opportunity for global infant health equity. [PDF]
Kumari S, Kamil KA.
europepmc +1 more source
Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants' First RSV Season in the UK. [PDF]
Chetty M +4 more
europepmc +1 more source
RSV Prevention in Infants and Young Children. [PDF]
Cacho F, Sockrider M.
europepmc +1 more source
Virus-like Particle Vaccines Containing RSV Fusion Protein Cleavage Mutations Are Immunogenic and Protective in Cotton Rats With a Prime Dose. [PDF]
Hwang HS +6 more
europepmc +1 more source
Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner. [PDF]
Paes BA +4 more
europepmc +1 more source
Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom. [PDF]
Hudson RDA +4 more
europepmc +1 more source

